Background: Sub-scleral trabeculectomy is the standard surgical procedure for management of uncontrolled primary open angle glaucoma (OAG). Intraoperative mitomycin–C is frequently used during sub-scleral trabeculectomy to decrease the risk of recurrence.
Objective: This study aimed to assess the impact of mitomycin-C levels used during subscleral trabeculectomy on managing intraocular pressure in primary open angle glaucoma cases.
Patients and methods: This study is a prospective comparative interventional and non-randomized study. It was carried out between March 2023 and August 2023. It was conducted on 30 eyes of 30 patients with uncontrolled open angle glaucoma. They were operated upon by sub-scleral trabeculectomy with intraoperative mitomycin–C.  Patients were divided into three equal groups according to the mitomycin–C concentration: Group A[10 patient] received 0.2 mg/ml mitomycin-C. Group B [10 patient] received 0.3 mg/ml mitomycin-C.Group C[10 patient] received 0.4 mg/ml mitomycin-C.
Results: There were statistically non-significant differences between group A, B and C as regards age, sex and preoperative IOP. Statistically highly significant IOP decrease was detected in all groups one day postoperatively and continued till the end of follow-up period at 3 months postoperatively as compared to preoperative level. There were statistically non-significant differences between groups A, B and C as regards the IOP, UCVA and BCVA at the postoperative follow-up visits.
Conclusion: Different concentrations of mitomycin-C (0.2, 0.3, 0.4 mg/ml) were clinically equaled in controlling IOP after glaucoma surgery.